title: [Current diagnosis and treatment of migraine].
abstract: Headaches are one of the most common disorders and symptoms in daily medical practice. The prevalence of migraine is 8% in men and 12-15% in women. Dramatic progress in the areas of epidemiology, pathophysiology, and acute and preventive therapy of migraine has been made over the past 100 years, with triptans being the breakthrough for treating acute migraine attacks. Beta blockers, calcium antagonists, and neuromodulators are available for preventive migraine therapy. Nonpharmacologic treatment also plays an important role in migraine prevention. New medical care structures such as integrated headache care provide better support for patients with migraine, particularly those with chronic migraine.
authors.affiliation: Universitätsklinik für Neurologie und Westdeutsches Kopfschmerzzentrum, Universitätsklinikum Essen, Hufelandstrasse 55, 45147, Essen, Germany. h.diener@uni-essen.de
authors.forename: H-C
authors.initials: HC
authors.lastname: Diener
authors.forename: Z
authors.initials: Z
authors.lastname: Katsarava
authors.forename: V
authors.initials: V
authors.lastname: Limmroth
mesh_terms: D015670:Acupuncture Therapy; D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D001521:Behavior Therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D015897:Comorbidity; D003863:Depression / Q000150:complications / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D018377:Neurotransmitter Agents / Q000627:therapeutic use; D015995:Prevalence; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D012737:Sex Factors; D018170:Sumatriptan / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D002121:Calcium Channel Blockers; D018377:Neurotransmitter Agents; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan